RecruitingPhase 4NCT03781752
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Sponsor
Icahn School of Medicine at Mount Sinai
Enrollment
500 participants
Start Date
Mar 4, 2018
Study Type
INTERVENTIONAL
Conditions
Summary
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Eligibility
Min Age: 6 YearsMax Age: 17 Years
Inclusion Criteria1
- \- Youth ages 6-17 years with ADHD as a primary diagnosis
Exclusion Criteria3
- Participants that do not have ADHD as a primary diagnosis
- Participants that do not want, require, or are not healthy enough for a single dose trial of MPH for ADHD per the clinical judgment of the treating and study clinicians
- Participants that are smokers or, are pregnant
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGMethylphenidate
study to determine dose
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03781752
Related Trials
Trauma-adapted Yoga in Child & Adolescent Psychiatry.
NCT063307791 location
Investigating Health, Equity, and Resilience in Girls and Women With ADHD Across the Lifespan
NCT075977071 location
Intensive-neurofeedback Protocol for Children With ADHD: A Proof-of-concept Study Comparing iAPF-personalized and Standard Theta-beta-ratio Training
NCT075957832 locations
ADHD&me: Targeting Self-esteem in Youth With ADHD
NCT075041071 location
Testing a Measurement Feedback App to Improve Data Quality, Supervision & Outcomes in Behavioral Health
NCT070423471 location